Wang Jie, Lu Lingxiao, Wu Ruicheng, Li Dengxiong, Wang Zhipeng, Ye Luxia, Feng Dechao
Department of Urology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, Zhejiang, China.
Department of Urology, Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
Front Immunol. 2025 Aug 27;16:1642193. doi: 10.3389/fimmu.2025.1642193. eCollection 2025.
Immunoglobulin superfamily member 8 (IGSF8) is a membrane protein implicated in crucial biological processes like cell interactions and immune responses. Emerging evidence suggests that IGSF8 plays a significant role in various cancers by influencing tumor progression through regulation of cell proliferation, migration, and apoptosis. Analyzing its expression, mutation status, and clinical correlations across different cancer types through pan-cancer bioinformatics could provide valuable insights into its potential as a biomarker and target for cancer therapies.
In this study, we utilized several public databases to investigate the biological role of IGSF8, focusing on its associations with prognosis, tumor heterogeneity, stemness, immune checkpoint genes, and immune cell infiltration across different types of cancer. Additionally, the GDSC and CTRP databases were employed to assess the sensitivity of IGSF8 to small molecule drugs. CCK8 assay and colony formation assay were used to detect its biological effect on cancer cells.
IGSF8 was significantly upregulated in 23 types of cancers and associated with poor prognosis in several cancers, including cell carcinoma and endocervical adenocarcinoma (CESC) and Acute Myeloid Leukemia(LAML). Its high expression was linked to multiple immune regulatory genes and immune checkpoint genes in the tumor microenvironment, with a notable positive correlation with CD276 in most cancers. IGSF8 was also closely associated with multiple indicators of tumor heterogeneity, stemness, as well as significant RNA methylation modifications across various cancers. Drug sensitivity analysis identified BX-795 and tozasertib as potential treatments for tumors with high IGSF8 expression. Knockdown of IGSF8 significantly inhibited the proliferation ability of prostate cancer cells.
Our findings indicated that IGSF8 might be used as a potential prognostic marker and therapeutic target for various cancers.
免疫球蛋白超家族成员8(IGSF8)是一种膜蛋白,参与细胞相互作用和免疫反应等关键生物学过程。新出现的证据表明,IGSF8通过调节细胞增殖、迁移和凋亡影响肿瘤进展,在多种癌症中发挥重要作用。通过泛癌生物信息学分析其在不同癌症类型中的表达、突变状态及临床相关性,可为其作为癌症生物标志物和治疗靶点的潜力提供有价值的见解。
在本研究中,我们利用多个公共数据库研究IGSF8的生物学作用,重点关注其与不同类型癌症的预后、肿瘤异质性、干性、免疫检查点基因及免疫细胞浸润的关联。此外,使用GDSC和CTRP数据库评估IGSF8对小分子药物的敏感性。采用CCK8测定法和集落形成测定法检测其对癌细胞的生物学效应。
IGSF8在23种癌症中显著上调,在包括细胞癌、宫颈内膜腺癌(CESC)和急性髓系白血病(LAML)等多种癌症中与不良预后相关。其高表达与肿瘤微环境中的多个免疫调节基因和免疫检查点基因相关,在大多数癌症中与CD276呈显著正相关。IGSF8还与多种癌症的肿瘤异质性、干性指标以及显著的RNA甲基化修饰密切相关。药物敏感性分析确定BX - 795和托扎替布为IGSF8高表达肿瘤的潜在治疗药物。敲低IGSF8可显著抑制前列腺癌细胞的增殖能力。
我们的研究结果表明,IGSF8可能作为多种癌症的潜在预后标志物和治疗靶点。